GKWIM
ALNY icon

Gerber Kawasaki Wealth & Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Gerber Kawasaki Wealth & Investment Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2
Closed – – 310
2021
Q3 		$0 Buy
+2
New +$375 ﹤0.01% 1168

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Gerber Kawasaki Wealth & Investment Management's ALNY Position: Q4 2021 in Review

Gerber Kawasaki Wealth & Investment Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2021, closing a stake of 2 shares.

Gerber Kawasaki Wealth & Investment Management first reported a position in ALNY in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 434 funds tracked by Wall St. Rank hold ALNY as of Q4 2021.

  • Gerber Kawasaki Wealth & Investment Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Gerber Kawasaki Wealth & Investment Management sold 2 Alnylam Pharmaceuticals shares in Q4 2021.
  • Gerber Kawasaki Wealth & Investment Management first reported a position in Alnylam Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • Gerber Kawasaki Wealth & Investment Management's Alnylam Pharmaceuticals position peaked at $0 in Q3 2021.
  • 434 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2021.

Based on Gerber Kawasaki Wealth & Investment Management's 13F filing for Q4 2021, filed 11 Feb 2022.